AstraZeneca, MSD sue MSN and Sandoz over Calquence generics

AstraZeneca and Merck, Sharp & Dohme (MSD) have filed a pair of lawsuits against MSN and Sandoz, claiming their planned generic versions of its leukaemia treatment Calquence (acalabrutinib) infringe six patents.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Generics

MSD targets Mankind’s diabetes generic in patent suit

5 April 2022 Merck Sharp & Dohme has filed a complaint against New Dehli-based Mankind Pharma, looking to halt the approval of a generic version of the type two diabetes treatment, Januvia.

Big Pharma

MSD prevails in diabetes drug dispute with Mylan

29 September 2022 MSD, known as Merck in the US and Canada, has won against a case concerning branded diabetes treatment Janumet XR at the US Court of Appeals for the Federal Circuit.

Americas

MSD wins patent extension feud over post-surgery drug

15 June 2023 The three-year dispute revolved around proposed generic versions of a drug used to offset the effects of muscle relaxants | Pharma giant can retain patent until January 2026.

More on this story

Generics

MSD targets Mankind’s diabetes generic in patent suit

5 April 2022 Merck Sharp & Dohme has filed a complaint against New Dehli-based Mankind Pharma, looking to halt the approval of a generic version of the type two diabetes treatment, Januvia.

Big Pharma

MSD prevails in diabetes drug dispute with Mylan

29 September 2022 MSD, known as Merck in the US and Canada, has won against a case concerning branded diabetes treatment Janumet XR at the US Court of Appeals for the Federal Circuit.

Americas

MSD wins patent extension feud over post-surgery drug

15 June 2023 The three-year dispute revolved around proposed generic versions of a drug used to offset the effects of muscle relaxants | Pharma giant can retain patent until January 2026.

More on this story

Generics

MSD targets Mankind’s diabetes generic in patent suit

5 April 2022 Merck Sharp & Dohme has filed a complaint against New Dehli-based Mankind Pharma, looking to halt the approval of a generic version of the type two diabetes treatment, Januvia.

Big Pharma

MSD prevails in diabetes drug dispute with Mylan

29 September 2022 MSD, known as Merck in the US and Canada, has won against a case concerning branded diabetes treatment Janumet XR at the US Court of Appeals for the Federal Circuit.

Americas

MSD wins patent extension feud over post-surgery drug

15 June 2023 The three-year dispute revolved around proposed generic versions of a drug used to offset the effects of muscle relaxants | Pharma giant can retain patent until January 2026.

More features

Chinese biotech takes out US rival’s nucleic acid patent at PTAB

Lewis Roca promotes tech expert to managing partner

Panitch Schwarze brings in molecular biologist

US targets ‘product hopping’ with biologic litigation curbs

UPC confirms validity of Edwards Lifesciences heart valve tech patent

ITC concludes row over biotech lab equipment between US and German rivals

UKIPO launches ‘revolutionary’ patent filing and AI tool

USPTO clarifies AI's role in patent eligibility

AstraZeneca, MSD sue MSN and Sandoz over Calquence generics

More on this story

Editor's picks

Editor's picks

More on this story

More on this story

More features